Cargando…

Expression of Bruton´s tyrosine kinase in different type of brain lesions of multiple sclerosis patients and during experimental demyelination

BACKGROUND: Inhibition of Bruton’s tyrosine kinase (BTK) is an emerging multiple sclerosis (MS) therapy. BTK inhibitors (BTKi) cross the blood-brain barrier and modulate B cells and microglia, major cellular players in active and chronic active lesions. OBJECTIVE: To assess potential lesional and ce...

Descripción completa

Detalles Bibliográficos
Autores principales:	Elkjaer, Maria L., Waede, Mie R., Kingo, Christina, Damsbo, Karina, Illes, Zsolt
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679451/ https://www.ncbi.nlm.nih.gov/pubmed/38022591 http://dx.doi.org/10.3389/fimmu.2023.1264128

Ejemplares similares

Targeting Bruton’s Tyrosine Kinase in CLL
por: Ahn, Inhye E., et al.
Publicado: (2021)

Bruton’s Tyrosine Kinase Inhibition in Multiple Sclerosis
por: Schneider, Raphael, et al.
Publicado: (2022)

Bruton tyrosine kinase inhibitors for multiple sclerosis
por: Krämer, Julia, et al.
Publicado: (2023)

Bruton’s tyrosine kinase inhibitors in the treatment of multiple sclerosis
por: Shulga, Olga, et al.
Publicado: (2023)

Editorial: New Insights on Bruton’s Tyrosine Kinase Inhibitors
por: Smith, C. I. Edvard, et al.
Publicado: (2021)

Bruton’s Tyrosine Kinase: An Emerging Key Player in Innate Immunity
por: Weber, Alexander N. R., et al.
Publicado: (2017)

A Systematic Review of Tissue and Single Cell Transcriptome/Proteome Studies of the Brain in Multiple Sclerosis
por: Elkjaer, Maria L., et al.
Publicado: (2022)

Distinct Roles for Bruton's Tyrosine Kinase in B Cell Immune Synapse Formation
por: Roman-Garcia, Sara, et al.
Publicado: (2018)

Bruton’s Tyrosine Kinase Supports Gut Mucosal Immunity and Commensal Microbiome Recognition in Autoimmune Arthritis
por: Bonami, Rachel H., et al.
Publicado: (2022)

Targeting Multiple End Organs in Lupus and Other Systemic Rheumatic Diseases by Inhibiting Bruton’s Tyrosine Kinase
por: Du, Yong, et al.
Publicado: (2022)

Bruton’s Tyrosine Kinase Targeting in Multiple Myeloma
por: Von Suskil, Max, et al.
Publicado: (2021)

Second-generation inhibitors of Bruton tyrosine kinase
por: Wu, Jingjing, et al.
Publicado: (2016)

Experimental Demyelination and Axonal Loss Are Reduced in MicroRNA-146a Deficient Mice
por: Martin, Nellie A., et al.
Publicado: (2018)

Bruton’s Tyrosine Kinase, a Component of B Cell Signaling Pathways, Has Multiple Roles in the Pathogenesis of Lupus
por: Satterthwaite, Anne B.
Publicado: (2018)

Bruton's Tyrosine Kinase Inhibition Attenuates the Cardiac Dysfunction Caused by Cecal Ligation and Puncture in Mice
por: O'Riordan, Caroline E., et al.
Publicado: (2019)

Inhibition of Bruton’s tyrosine kinase interferes with pathogenic B-cell development in inflammatory CNS demyelinating disease
por: Torke, Sebastian, et al.
Publicado: (2020)

Bruton’s tyrosine kinase inhibition reduces disease severity in a model of secondary progressive autoimmune demyelination
por: Evonuk, Kirsten Scarlett, et al.
Publicado: (2023)

Bruton's tyrosine kinase: oncotarget in myeloma
por: Tai, Yu-Tzu, et al.
Publicado: (2012)

Editorial: Targeting Bruton Tyrosine Kinase
por: Brunner, Cornelia, et al.
Publicado: (2022)

Bruton’s Tyrosine Kinase Inhibitors in Multiple Sclerosis: Pioneering the Path Towards Treatment of Progression?
por: Geladaris, Anastasia, et al.
Publicado: (2022)

X-Linked Immunodeficient Mice With No Functional Bruton's Tyrosine Kinase Are Protected From Sepsis-Induced Multiple Organ Failure
por: O'Riordan, Caroline E., et al.
Publicado: (2020)

Bruton’s Tyrosine Kinase Inhibitors: A New Generation of Promising Agents for Multiple Sclerosis Therapy
por: García-Merino, Antonio
Publicado: (2021)

Regulatory Phosphorylation of Ikaros by Bruton's Tyrosine Kinase
por: Ma, Hong, et al.
Publicado: (2013)

Bruton’s Tyrosine Kinase and Its Isoforms in Cancer
por: Wang, Xianhui, et al.
Publicado: (2021)

Bruton’s Tyrosine Kinase-Mediated Signaling in Myeloid Cells Is Required for Protective Innate Immunity During Pneumococcal Pneumonia
por: de Porto, Alexander P., et al.
Publicado: (2021)

Altered Expression of Ion Channels in White Matter Lesions of Progressive Multiple Sclerosis: What Do We Know About Their Function?
por: Boscia, Francesca, et al.
Publicado: (2021)

Bruton’s Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia
por: Naylor-Adamson, Leigh, et al.
Publicado: (2021)

Role of Bruton's Tyrosine Kinase in B Cell Development
por: Maas, Alex, et al.
Publicado: (2001)

Novel Bruton’s tyrosine kinase inhibitors currently in development
por: D’Cruz, Osmond J, et al.
Publicado: (2013)

Role of Bruton’s tyrosine kinase in B cells and malignancies
por: Pal Singh, Simar, et al.
Publicado: (2018)

Bruton’s Tyrosine Kinase Inhibition Promotes Myelin Repair
por: Martin, Elodie, et al.
Publicado: (2020)

Bruton’s Tyrosine Kinase Inhibition for the Treatment of Rheumatoid Arthritis
por: Arneson, Laura C, et al.
Publicado: (2021)

Targeting Bruton’s Tyrosine Kinase in Inflammatory and Autoimmune Pathologies
por: Neys, Stefan F. H., et al.
Publicado: (2021)

The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
por: Khan, Abdullah Mohammad
Publicado: (2022)

The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
por: Ababneh, Obada, et al.
Publicado: (2022)

Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia
por: Castillo, Jorge J., et al.
Publicado: (2023)

Targeting Spleen Tyrosine Kinase-Bruton's Tyrosine Kinase Axis for Immunologically Mediated Glomerulonephritis
por: Chen, Jin-Shuen, et al.
Publicado: (2014)

Bruton’s tyrosine kinase inhibition attenuates disease progression by reducing renal immune cell invasion in mice with hemolytic-uremic syndrome
por: Kröller, Sarah, et al.
Publicado: (2023)

Bruton's tyrosine kinase inhibition induces rewiring of proximal and distal B‐cell receptor signaling in mice
por: Rip, Jasper, et al.
Publicado: (2021)

Risk of HBV reactivation in relapsed or refractory diffuse large B-cell lymphoma patients receiving Bruton tyrosine kinase inhibitors therapy
por: Ni, Ying, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_brvbgfkfmbhucbjav48vf07kjt